Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation
Active, enrolledPhase 2Results postedLast updated 6 November 2025
What this trial tests
Phase 2 trial testing Abelacimab in Atrial Fibrillation (AF) in 1,287 participants. Participants enrolled and being followed up; not accepting new ones.
55 and older, any sex, with Atrial Fibrillation (AF) or Stroke. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Incidence Rate of the First Occurrence of Composite of International Society on Thrombosis and Haemostasis (ISTH)-Defined Major Bleeding or Clinically Relevant Non-Major (CRNM) Bleeding EventsPrimary· Assessed at every visit from randomization through the end of the randomized phase of the study, up to 33 months.
The number of participants experiencing the first occurrence of the composite of ISTH-defined major bleeding or CRNM bleeding events divided by the number of 100 person-years through the first event or end of treatment across all participants, is presented. For participants not experiencing events, person-years is calculated through the end of treatment during the randomized phase.
Group
Value
95% CI
Abelacimab 90 mg (MAA868)
2.64
Abelacimab 150 mg (MAA868)
3.22
Rivaroxaban
8.39
Incidence Rate of the First Occurrence of ISTH-defined Major Bleeding EventsSecondary· Assessed at every visit from randomization through the end of the randomized phase of the study, up to 33 months.
The number of participants experiencing the first occurrence of ISTH-defined major bleeding events divided by the number of 100 person-years through the first event or end of treatment across all participants, is presented. For participants not experiencing events, person-years is calculated through the end of treatment during the randomized phase.
Group
Value
95% CI
Abelacimab 90 mg (MAA868)
0.99
Abelacimab 150 mg (MAA868)
1.22
Rivaroxaban
3.73
Incidence Rate of the First Occurrence of ISTH-defined Major or CRNM or Minor Bleeding EventsSecondary· Assessed at every visit from randomization through the end of the randomized phase of the study, up to 33 months.
The number of participants experiencing the first occurrence of the composite of ISTH-defined major or CRNM or minor bleeding events divided by the number of 100 person-years through the first event or end of treatment across all participants, is presented. For participants not experiencing events, person-years is calculated through the end of treatment during the randomized phase.
Group
Value
95% CI
Abelacimab 90 mg (MAA868)
7.05
Abelacimab 150 mg (MAA868)
10.43
Rivaroxaban
15.30
Adverse events — posted to ClinicalTrials.gov
Time frame: Adverse events (AEs) that started during or after the start of the treatment or started prior to the start of the treatment and increased in severity after the start of the treatment through each participant's derived End of Study date for the randomized period (up to 33 months)..
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The purpose of the ANT-006 study is to evaluate the bleeding profile of abelacimab relative to rivaroxaban in patients with atrial fibrillation (AF) at moderate-to-high risk of stroke.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT05712200 — Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Dee
· Phase 3
· recruiting
NCT05171075 — A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
· Phase 3
· terminated
NCT05171049 — A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
· Phase 3
· terminated
Other recruiting trials for Atrial Fibrillation (AF)
Currently open trials in the same condition.
NCT07298473 — Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sp
· NA
· recruiting
NCT05712200 — Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Dee
· Phase 3
· recruiting
NCT05171075 — A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
· Phase 3
· terminated
NCT05421533 — Study in Atrial Fibrillation (AF) Patients at High Risk of Stroke
· terminated
NCT05171049 — A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
· Phase 3
· terminated
NCT04213807 — A Dose-range Finding Study of MAA868 in Patients With Atrial Fibrillation
· Phase 2
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Anthos Therapeutics, Inc.
Last refreshed: 6 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04755283.